Inspirion Wealth Advisors LLC raised its stake in shares of Glaukos Corp (NYSE:GKOS) by 7.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,400 shares of the medical instruments supplier’s stock after buying an additional 650 shares during the period. Inspirion Wealth Advisors LLC’s holdings in Glaukos Corp were worth $482,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. State Board of Administration of Florida Retirement System raised its position in Glaukos Corp by 1.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 7,699 shares of the medical instruments supplier’s stock valued at $264,000 after buying an additional 140 shares during the last quarter. First Republic Investment Management Inc. raised its position in Glaukos Corp by 9.1% in the fourth quarter. First Republic Investment Management Inc. now owns 12,613 shares of the medical instruments supplier’s stock valued at $432,000 after buying an additional 1,047 shares during the last quarter. Teachers Advisors LLC raised its position in Glaukos Corp by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock valued at $953,000 after buying an additional 1,506 shares during the last quarter. Great West Life Assurance Co. Can acquired a new position in Glaukos Corp during the first quarter valued at approximately $102,000. Finally, American Century Companies Inc. raised its position in Glaukos Corp by 2.6% in the first quarter. American Century Companies Inc. now owns 135,082 shares of the medical instruments supplier’s stock valued at $6,930,000 after buying an additional 3,458 shares during the last quarter. 77.95% of the stock is owned by institutional investors and hedge funds.
Shares of Glaukos Corp (NYSE:GKOS) traded down 1.23% during mid-day trading on Friday, reaching $36.83. 519,656 shares of the company traded hands. The firm’s 50 day moving average price is $45.13 and its 200-day moving average price is $40.81. The company has a market capitalization of $1.26 billion, a P/E ratio of 334.82 and a beta of 1.37. Glaukos Corp has a 52-week low of $23.47 and a 52-week high of $52.49.
Glaukos Corp (NYSE:GKOS) last issued its earnings results on Wednesday, March 1st. The medical instruments supplier reported $0.00 earnings per share (EPS) for the quarter. Glaukos Corp had a return on equity of 2.05% and a net margin of 2.07%. The business had revenue of $33.17 million during the quarter, compared to analysts’ expectations of $29.49 million. During the same quarter in the previous year, the business earned ($0.07) EPS. The company’s revenue for the quarter was up 63.6% on a year-over-year basis. Equities analysts predict that Glaukos Corp will post $0.21 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Glaukos Corp (GKOS) Shares Bought by Inspirion Wealth Advisors LLC” was published by Mideast Time and is the property of of Mideast Time. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.mideasttime.com/glaukos-corp-gkos-shares-bought-by-inspirion-wealth-advisors-llc/1709069.html.
Several research firms have recently commented on GKOS. Cantor Fitzgerald reissued an “overweight” rating and issued a $54.00 price objective on shares of Glaukos Corp in a research note on Thursday, May 4th. TheStreet lowered shares of Glaukos Corp from a “c” rating to a “d+” rating in a research note on Wednesday, May 3rd. Stifel Nicolaus raised their price objective on shares of Glaukos Corp from $45.00 to $55.00 and gave the company a “positive” rating in a research note on Tuesday, February 28th. Zacks Investment Research lowered shares of Glaukos Corp from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Finally, BMO Capital Markets began coverage on shares of Glaukos Corp in a research note on Wednesday, February 22nd. They issued an “outperform” rating and a $54.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $48.17.
In other news, Director Orbimed Advisors Llc sold 382,538 shares of the business’s stock in a transaction dated Tuesday, March 14th. The stock was sold at an average price of $45.33, for a total transaction of $17,340,447.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 36.80% of the stock is currently owned by insiders.
Glaukos Corp Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).
Receive News & Ratings for Glaukos Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp and related companies with MarketBeat.com's FREE daily email newsletter.